Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Codexis gets funds, sets R&D center
September 4, 2006
| A version of this story appeared in
Volume 84, Issue 36
Codexis has raised $37 million in a fourth round of financing and expects to raise another $3 million in the next 60 days. The investment round was led by BioOne Capital of Singapore; existing investors in the biocatalysis company also participated. Codexis says it will establish a biocatalyst R&D center, which is tied to the investment, in Singapore by the third quarter of 2007. When fully staffed, the firm says, the center will employ up to 80 people focused on development of active pharmaceutical ingredients for generic drugs. Codexis currently employs about 130 people.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter